Daehan Nupharm Q1 2026: Revenue and Net Profit Up, Comprehensive Loss Due to Investment Valuation

Q1 2026 revenue 54.8B KRW (+5.8% YoY), operating profit 3.1B (+19.2% YoY), net income 3.0B (+16.3% YoY), EPS 214 won
Total comprehensive loss of 0.34B KRW due to 4.3B valuation loss on FVOCI financial assets
Net debt 86.7B KRW, total equity 138.2B KRW, net debt-to-equity ratio 62.8%
CAPEX ongoing with 84.5B KRW in construction in progress (Hyangnam new plant)
Companion animal stem cell therapy 'Newstem' in clinical trials, targeting approval in 2027
No share buyback or cancellation plan; final dividend paid for FY2025 (amount undisclosed)
No significant litigation or contingent liabilities